^
    Back
    Association details:
    Biomarker:EZH2 mutation
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:CPI-169 (EZH2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    Abstract 2925: Safety and efficacy of EZH2 and BRD4 dual targeting in EZH2Y641mut germinal centre-derived lymphoma

    Published date:
    05/15/2020
    Excerpt:
    CPI169 induced dose-dependent proliferation blockade in EZH2mut, but not EZH2wt DLBCL and FL cell lines, independently of EZH2 expression level…CPI169 shows significant activity and safety as single agent in EZH2 mutated-DLBCL and FL cases...
    DOI:
    10.1158/1538-7445.AM2020-2925